A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

NCT04691648 · clinicaltrials.gov ↗

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

Interventions

DRUG: Gilteritinib Exposure

Sponsor

Astellas Pharma Korea, Inc.